Skip to content

BCBS Arkansas

Does BCBS Arkansas cover Wegovy?

Yes. BCBS Arkansas covers Wegovy for weight loss with prior authorization. Other policy requirements and your plan's benefits also apply.

Policy document

  • Employer and ACA Marketplace: Covered with requirements. See the qualification pathways below.

Earliest policy review June 2, 2026. How we verify · Check your exact plan

Full requirements: Wegovy for Weight Loss (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

Pediatric Weight Loss (ages 12-17) - Obesity

All of:

  • Patient is 12 to 17 years of age
  • Request is NOT for Wegovy HD 7.2 mg injection OR Wegovy tablets
  • Participated in a comprehensive weight management program (behavioral modification, reduced-calorie diet, increased physical activity) with continuing follow-up for at least 6 months prior to drug therapy
  • Baseline BMI ≥ 95th percentile standardized for age and sex (obesity) (if transitioning, use BMI at start of any drug therapy)
  • Used with a reduced-calorie diet AND increased physical activity

Documentation to bring

  • Baseline BMI documentation at or above the 95th percentile standardized for age and sex (if transitioning from another weight loss drug, BMI at start of any drug therapy)
  • Documentation of BMI reduction from baseline or maintenance of initial BMI reduction (for continuation)

Quantity limits

  • 0.25mg/0.5mL, 0.5mg/0.5mL, 1mg/0.5mL — 2 mL (1 package of 4 pens) / 21 days; 6 mL (3 packages of 4 pens each) / 63 days (84-day)
  • 1.7mg/0.75mL, 2.4mg/0.75mL — 3 mL (1 package of 4 pens) / 21 days; 9 mL (3 packages of 4 pens each) / 63 days (84-day)

Approval and renewal

  • Initial approval: 7 months
  • Renewal: every 12 months
  • Renewal: Patient must have successfully titrated to a stable maintenance dose AND had a reduction from baseline BMI OR continued to maintain their initial BMI reduction. Documentation required. Note: initial 6-month lifestyle program requirement and BMI percentile threshold are not re-verified at continuation.

Not covered when

  • Wegovy HD 7.2 mg injection is excluded for pediatric patients (ages 12-17)
  • Wegovy tablets are excluded for pediatric patients (ages 12-17)
  • Concomitant use with other semaglutide-containing products is not recommended
  • Concomitant use with any other GLP-1 receptor agonist is not recommended

Policy note: This entry covers the pediatric weight loss indication only (ages 12-17), which is restricted to Wegovy injection (excluding HD 7.2 mg) and excludes tablets. Continuation requires successful titration to stable maintenance dose and BMI reduction or maintenance.

verified June 2, 2026 · source: 4774 C Wegovy · View policy document (PDF)

Open on its own page →

Full requirements: Wegovy for Heart Disease Risk Reduction (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

CV Risk Reduction - Established CVD without T2DM

All of:

  • Patient is an adult (18 years or older)
  • Request is NOT for Wegovy HD 7.2 mg injection
  • Used with a reduced-calorie diet AND increased physical activity
  • Patient does NOT have type 2 diabetes (patients with T2DM should use Ozempic for CV risk reduction)
  • Baseline BMI ≥ 27 kg/m2 (obesity or overweight; if transitioning, use BMI at start of any drug therapy)
  • Patient is currently receiving GDMT for cardiovascular disease OR has a clinical reason not to be treated with GDMT

Plus any one of:

  • Previous MI
  • Previous stroke
  • Symptomatic PAD evidenced by intermittent claudication with ABI < 0.85 at rest, peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease
  • Prior history of revascularization (CABG, PCI, or angioplasty)

Documentation to bring

  • Documentation of qualifying CVD event (previous MI, previous stroke, symptomatic PAD with ABI < 0.85 or revascularization or amputation, or prior CABG/PCI/angioplasty)
  • Baseline BMI documentation (≥ 27 kg/m2; if transitioning, BMI at start of any drug therapy)
  • Documentation of current GDMT use (e.g., lipid-lowering agent, antiplatelet, beta-blocker, renin-angiotensin inhibitor) OR clinical reason GDMT is not appropriate
  • Confirmation that patient does NOT have type 2 diabetes

Quantity limits

  • 0.25mg/0.5mL, 0.5mg/0.5mL, 1mg/0.5mL — 2 mL (1 package of 4 pens) / 21 days; 6 mL (3 packages of 4 pens each) / 63 days (84-day)
  • 1.7mg/0.75mL, 2.4mg/0.75mL — 3 mL (1 package of 4 pens) / 21 days; 9 mL (3 packages of 4 pens each) / 63 days (84-day)
  • 1.5mg tablet, 4mg tablet, 9mg tablet, 25mg tablet — 30 tablets / 25 days; 90 tablets / 75 days (84-day)

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • Renewal: At continuation, patient must still have established CV disease with a qualifying event history AND be on a maintenance dose based on individual treatment response and tolerability. Used with reduced-calorie diet and increased physical activity. Note: T2DM exclusion and GDMT requirement are NOT re-verified at continuation per the policy's continuation criteria (continuation criteria only re-check CV event history and maintenance dose, not GDMT or T2DM exclusion).

Not covered when

  • Wegovy HD 7.2 mg injection is excluded for this indication
  • Type 2 diabetes patients are directed to Ozempic for CV risk reduction instead
  • Concomitant use with other semaglutide-containing products is not recommended
  • Concomitant use with any other GLP-1 receptor agonist is not recommended

Policy note: Both Wegovy injection and Wegovy tablets are covered for CV risk reduction in adults, but Wegovy HD 7.2 mg injection is explicitly excluded for this indication. The policy notes that Ozempic is indicated for CV risk reduction in adults with T2DM and established CVD; Wegovy CV risk reduction explicitly excludes patients with T2DM. GDMT examples listed: lipid-lowering agent, antiplatelet, beta-blocker, renin-angiotensin inhibitor. DOA is 12 months for both initial and continuation.

verified June 2, 2026 · source: 4774 C Wegovy · View policy document (PDF)

Open on its own page →

Full requirements: Wegovy for Liver Disease (MASH) (2 plan types)

Applies to Employer and ACA Marketplace plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

MASH with F2-F3 Fibrosis - Adult

All of:

  • Patient is an adult (18 years or older)
  • Request is NOT for Wegovy HD 7.2 mg injection OR Wegovy tablets
  • Used with a reduced-calorie diet AND increased physical activity
  • Diagnosis of noncirrhotic MASH (formerly NASH) with moderate to advanced liver fibrosis (stages F2 to F3)
  • Prescribed by or in consultation with a gastroenterologist or hepatologist
  • Moderate to advanced liver fibrosis (F2-F3) confirmed at baseline by non-invasive liver disease assessment (e.g., ultrasound-based elastography or MRE) OR historical liver biopsy

Documentation to bring

  • Documentation of baseline moderate to advanced liver fibrosis (F2-F3) confirmed by non-invasive liver disease assessment (ultrasound-based elastography or MRE) OR historical liver biopsy
  • Prescriber attestation of gastroenterologist or hepatologist involvement (prescribing or consulting)
  • Documentation of positive clinical response (e.g., reduction in ALT, improvement in ELF score, improvement in liver stiffness by elastography or MRE) (for continuation)

Quantity limits

  • 0.25mg/0.5mL, 0.5mg/0.5mL, 1mg/0.5mL — 2 mL (1 package of 4 pens) / 21 days; 6 mL (3 packages of 4 pens each) / 63 days (84-day)
  • 1.7mg/0.75mL, 2.4mg/0.75mL — 3 mL (1 package of 4 pens) / 21 days; 9 mL (3 packages of 4 pens each) / 63 days (84-day)

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • Renewal: Patient must have achieved or maintained a positive clinical response (e.g., improvement in liver function such as reduction in ALT, improvement in ELF score, improvement in liver stiffness measurement by ultrasound-based elastography or MRE). Patient must be on a maintenance dose based on individual treatment response and tolerability. Documentation required. Note: initial fibrosis confirmation (F2-F3) and specialist requirement are not explicitly re-verified at continuation.

Not covered when

  • Wegovy HD 7.2 mg injection is explicitly excluded for the MASH indication
  • Wegovy tablets are explicitly excluded for the MASH indication
  • Cirrhotic patients are excluded (noncirrhotic MASH only)
  • Concomitant use with other semaglutide-containing products is not recommended
  • Concomitant use with any other GLP-1 receptor agonist is not recommended

Policy note: MASH indication is restricted to Wegovy injection (standard strengths only); Wegovy HD 7.2 mg injection and Wegovy tablets are explicitly excluded. No specific lookback periods are stated for fibrosis confirmation; historical biopsy is acceptable. Fibrosis confirmation methods include ultrasound-based elastography (FibroScan VCTE), MRE, or historical liver biopsy. The policy notes this indication was approved under accelerated approval and continued approval may be contingent on confirmatory trial results. DOA is 12 months for both initial and continuation.

verified June 2, 2026 · source: 4774 C Wegovy · View policy document (PDF)

Open on its own page →

Questions people ask
Does BCBS Arkansas cover Wegovy?
Yes. BCBS Arkansas covers Wegovy for weight loss with prior authorization. Other policy requirements and your plan's benefits also apply.
How long does a Wegovy approval last with BCBS Arkansas?
Weight Loss — Applies to Employer and ACA Marketplace plans. Initial approval: 7 months. Renewal: every 12 months. Heart Disease Risk Reduction — Applies to Employer and ACA Marketplace plans. Initial approval: 12 months. Renewal: every 12 months. Liver Disease (MASH) — Applies to Employer and ACA Marketplace plans. Initial approval: 12 months. Renewal: every 12 months.
What does BCBS Arkansas require to renew Wegovy?
Weight Loss — Applies to Employer and ACA Marketplace plans. Patient must have successfully titrated to a stable maintenance dose AND had a reduction from baseline BMI OR continued to maintain their initial BMI reduction. Documentation required. Note: initial 6-month lifestyle program requirement and BMI percentile threshold are not re-verified at continuation. Heart Disease Risk Reduction — Applies to Employer and ACA Marketplace plans. At continuation, patient must still have established CV disease with a qualifying event history AND be on a maintenance dose based on individual treatment response and tolerability. Used with reduced-calorie diet and increased physical activity. Note: T2DM exclusion and GDMT requirement are NOT re-verified at continuation per the policy's continuation criteria (continuation criteria only re-check CV event history and maintenance dose, not GDMT or T2DM exclusion). Liver Disease (MASH) — Applies to Employer and ACA Marketplace plans. Patient must have achieved or maintained a positive clinical response (e.g., improvement in liver function such as reduction in ALT, improvement in ELF score, improvement in liver stiffness measurement by ultrasound-based elastography or MRE). Patient must be on a maintenance dose based on individual treatment response and tolerability. Documentation required. Note: initial fibrosis confirmation (F2-F3) and specialist requirement are not explicitly re-verified at continuation.
How current is this information?
The oldest review date among the policies on this page is June 2, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under BCBS Arkansas: Mounjaro, Ozempic, Zepbound

Wegovy under other plans: BCBS Alabama, BCBS Arizona, BCBS Louisiana, BCBS Massachusetts, BCBS Michigan, BCBS Minnesota, BCBS Nebraska, BCBS North Carolina

All insurance plans · All medications

Summary of BCBS Arkansas's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.